E-GEOD-51627
Ontology highlight
ABSTRACT:
PROVIDER: E-GEOD-51627 | ExpressionAtlas | 2015-07-27
REPOSITORIES: ExpressionAtlas
Similar Datasets
Project description:Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment
Lisette dePillis 1, , Trevor Caldwell 2, , Elizabeth Sarapata 2, and Heather Williams 2,
1.
Department of Mathematics, Harvey Mudd College, Claremont, CA 91711
2.
Harvey Mudd College, Claremont, CA 91711, United States, United States, United States
Abstract
We present a mathematical model to study the effects of the regulatory T cells (Treg) on Renal Cell Carcinoma (RCC) treatment with sunitinib. The drug sunitinib inhibits the natural self-regulation of the immune system, allowing the effector components of the immune system to function for longer periods of time. This mathematical model builds upon our non-linear ODE model by de Pillis et al. (2009) [13] to incorporate sunitinib treatment, regulatory T cell dynamics, and RCC-specific parameters. The model also elucidates the roles of certain RCC-specific parameters in determining key differences between in silico patients whose immune profiles allowed them to respond well to sunitinib treatment, and those whose profiles did not.
Simulations from our model are able to produce results that reflect clinical outcomes to sunitinib treatment such as: (1) sunitinib treatments following standard protocols led to improved tumor control (over no treatment) in about 40% of patients; (2) sunitinib treatments at double the standard dose led to a greater response rate in about 15% the patient population; (3) simulations of patient response indicated improved responses to sunitinib treatment when the patient's immune strength scaling and the immune system strength coefficients parameters were low, allowing for a slightly stronger natural immune response.
Keywords: Renal cell carcinoma, mathematical modeling., sunitinib, immune system, regulatory T cells.
2020-01-06 | BIOMD0000000908 | BioModels
Project description:Treatment of renal cell carcinoma cell line A-498 with zebularine
| PRJNA224109 | ENA
Project description:This analysis was performed among 786-o renal cell carcinoma cell line, its sunitinib resistant cell, and sunitinib resistant Hif2a knock out cell.
2017-08-09 | PXD007222 | JPOST Repository
Project description:This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts.
Active cohorts: Escalation revised dosing regimen cohort.
Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy), gastric/gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first line) and escalation phase .
| 2138571 | ecrin-mdr-crc
Project description:To find out the potential targets in response to estrogen treatment on ACHN cell, a human renal cell carcinoma (RCC) cell line. Since estrogen can repress ACHN growth in a partly estrogen receptor-dependent manner, it is possible that phosphorylation state in ACHN cells is regulated.
2016-04-26 | PXD001962 | Pride
Project description:In this project, we generated chronic sunitinib-treated 786-O cell, a renal cell carcinoma cell line. In order to investigate the possible effect of GPR30 agonist, G-1, on the growth-inhibtion related signaling pathways, we treated either parental both parental and chronic sunitinib-treated 786-O cells were treated either by vehicle-only (i.e. 0.1% DMSO) or 2 μM G-1 for 48 h. Therefore, there were three groups for comparison, including G-1 treatment (G-1 vs. parental), chronic sunitinib-treatment (SunR vs. parental), and G-1 treatment in SunR cells (SunR&G-1 vs. parental).
2021-08-14 | PXD020904 | JPOST Repository
Project description:The tyrosine kinase inhibitor sunitinib is an effective first-line treatment for patients with advanced renal cell carcinoma (RCC). Hypothesizing that a functional read-out by mass spectrometry-based (phospho, p-)proteomics will identify predictive biomarkers for treatment outcome of sunitinib, tumor tissues of 26 RCC patients were analyzed. Eight patients were primary resistant (RES) and 18 sensitive (SENS).
2024-01-26 | PXD043514 | Pride
Project description:Extracellular vesicles isolated from the supernatant of luciferase-expressing renal cell carcinoma cell line (786-O luc) and its bone metastatic variant (786-O BM) which was established by in vivo selection method. Extracellular vesicles were isolated using MagCapture.
2023-12-28 | PXD039106 | JPOST Repository
